| Soteria Biotherapeutics–Roche: investment, 202105 financing round Series A totalling $42m incl co-lead investor Roche Venture Fund |
2021-05-17 |
| Soteria Biotherapeutics–SEVERAL: investment, 202105 financing round Series A $42m co-led by Roche Venture Fund + 5AM Ventures |
2021-05-17 |
| Flare Therapeutics–Nextech: investment, 202105 financing round Series A totalling $82m incl co-investor Nextech Invest |
2021-05-13 |
| Flare Therapeutics–SEVERAL: investment, 202105 financing round Series A $82m led by Third Rock Ventures |
2021-05-13 |
| Biocatalysts Ltd–BRAIN Biotech: investment, 202105 acquisition addit 16.7% for £3.9m bringing total to 82.2% with 2 put options excercised |
2021-05-12 |
| AMSilk–Cargill: investment, 202105 financing round Series C totalling €29m incl new + co-investor Cargill |
2021-05-11 |
| AMSilk–ER Capital Holdings: investment, 202105 financing round Series C totalling €29m incl new + co-investor ER Capital Holdings |
2021-05-11 |
| AMSilk–MIG Fonds: investment, 202105 financing round Series C totalling €29m incl existing + co-investor MIG Verwaltungs AG |
2021-05-11 |
| AMSilk–Novo Group: investment, 202105 financing round Series C totalling €29m incl new + lead investor Novo Growth |
2021-05-11 |
| AMSilk–SEVERAL: investment, 202105 financing round Series C €29m led by Novo Growth with Cargill + ER Capital Holdings + MIG AG + Athos KG |
2021-05-11 |
| AMSilk–Strüngmann Group: investment, 202105 financing round Series C totalling €29m incl existing + co-investor Athos KG |
2021-05-11 |
| Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 |
2021-05-10 |
| BioNTech–Singapore (govt): grant, 202105– support from Singapore EDB for planned mRNA-based vaccine + therapeutics manufacturing plant in Singapore |
2021-05-10 |
| Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures |
2021-05-05 |
| Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science |
2021-05-05 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| APR Applied Pharma Research–Relief Therapeutics: investment, 202105– acquisition for CHF22m cash + CHF50m in shares binding term sheet signed |
2021-05-04 |
| ITM–Trophic Communications: public relations, 202105 service existent by Trophic Communications |
2021-05-04 |
| Labforward–Berlin (govt): investment, 202105 financing round Series B 2nd closing totalling >€3m incl existing + co-investor IBB Ventures |
2021-05-04 |
| Labforward–Fielmann Group: investment, 202105 financing round Series B 2nd closing totalling >€3m incl new + lead investor Fielmann Family Office |
2021-05-04 |
| Labforward–OTHER: investment, 202105 financing round Series B 2nd closing totalling >€3m incl existing + new business angels |
2021-05-04 |
| Labforward–SEVERAL: investment, 202105 financing round Series B 2nd closing >€3m led by Fielmann Family Office bringing total Series B to >€8.5m |
2021-05-04 |
| Oculis–BVCF Management: investment, 202105 financing round Series C totalling $57m incl new + co-lead investor BVCF Management |
2021-05-04 |
| Oculis–Hyfinity Investments: investment, 202105 financing round Series C totalling $57m incl new + co-lead investor Hyfinity Investments |
2021-05-04 |
| Oculis–SEVERAL: investment, 202105 financing round Series C $57m co-led by new investors BVCF Management + Hyfinity Investments |
2021-05-04 |
| Alto Neuroscience–Angermayer Group: investment, 202105 financing round Series A totalling $32m incl lead investor Apeiron Investment Group |
2021-05-03 |
| Alto Neuroscience–SEVERAL: investment, 202105 financing round Series A $32m with lead investor Apeiron Investment Group |
2021-05-03 |
| Celeris Therapeutics–Austria (govt): grant, 202105 grant €600k from aws |
2021-05-03 |
| MoonLake–BVF Partners: investment, 202105c financing round Series A incl lead investor BVF Partners |
2021-05-03 |
| MoonLake–Merck (DE): investment, 202105c financing round Series A incl co-investor Merck KGaA |
2021-05-03 |
| MoonLake–Merck (DE): sonelokimab, 202105– license from Merck KGaA |
2021-05-03 |
| MoonLake–Mo PR Advisory: public relations, 202105 service existent by Mo PR Advisory |
2021-05-03 |
| MoonLake–SEVERAL: investment, 202105c financing round Series A led by BVF Partners + incl Merck KGaA |
2021-05-03 |
| Aquila Biolabs–Scientific Industries: investment, 202104 acquisition of Aquila Biolabs GmbH by Scientific Bioprocessing Inc |
2021-04-30 |
| Valneva–SEVERAL: investment, 202104–202105 European private placement €26.895m with 2.445m ordinary shares at €11/share |
2021-04-29 |
| Valneva–SEVERAL: investment, 202104–202105 US IPO $61.24m+$14m with 2.32m+531k ADSs at $26.41/ADS as Nasdaq Global Select Market |
2021-04-29 |
| Boundless Bio–Nextech: investment, 202104 financing round Series B totalling $105m incl new + co-lead investor Nextech Invest |
2021-04-28 |
| Boundless Bio–SEVERAL: investment, 202104 financing round Series B $105m co-led by Nextech Invest + RA Capital Management |
2021-04-28 |
| Kaia Health–3VC: investment, 202104 financing round Series C totalling $75m incl existing + co-investor 3VC |
2021-04-28 |
| Kaia Health–A Round Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor A Round Capital |
2021-04-28 |
| Kaia Health–Balderton Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Balderton Capital |
2021-04-28 |
| Kaia Health–Eurazeo: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Eurazeo |
2021-04-28 |
| Kaia Health–Heartcore Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Heartcore Capital |
2021-04-28 |
| Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR |
2021-04-28 |
| Kaia Health–OTHER: investment, 202104 financing round Series C totalling $75m incl undisclosed growth equity fund as lead investor |
2021-04-28 |
| Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund |
2021-04-28 |
| Kaia Health–Symphony Ventures: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Symphony Ventures |
2021-04-28 |
| Kaia Health–UnitedHealth: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Optum Ventures |
2021-04-28 |
| Exciva–Andera Partners: investment, 202104 existent investment of Andera Partners |
2021-04-27 |
| PreComb Therapeutics–FiveT Capital: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor FiveT Capital |
2021-04-26 |
| PreComb Therapeutics–High-Tech Gründerfonds: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor HTGF |
2021-04-26 |
| PreComb Therapeutics–Kinled: investment, 202104 seed financing round totalling CHF2.2m incl co-lead investor Kinled Austria |
2021-04-26 |
| PreComb Therapeutics–SEVERAL: investment, 202104 seed financing round CHF2.2m led by Kinled Austria + HTGF + FiveT Capital |
2021-04-26 |
| Molecular Partners–SEVERAL: investment, 202104–202106 US IPO $63.75m+$9.56m with 3m+450k ADSs at $21.25/ADS at Nasdaq |
2021-04-23 |
| NLC Ventures–SEVERAL: investment, 202104 financing round €20m from family offices across Europe |
2021-04-23 |
| Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall |
2021-04-22 |
| Anavo Therapeutics–Merck (DE): investment, 202104 seed financing round totalling €20m incl co-lead investor M Ventures |
2021-04-22 |
| Anavo Therapeutics–SEVERAL: investment, 202104 seed financing round €20m led by M Ventures + Inkef Capital |
2021-04-22 |
| CeQur–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| Deep Instinct–SEVERAL: investment, 202104 financing round Series D $100m led by funds + accounts managed by BlackRock |
2021-04-22 |
| Endeavour Vision–SEVERAL: investment, 202104 closing of Endeavour Medtech Growth II fund at $375m |
2021-04-22 |
| IntelyCare–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| ITM–Petrichor Healthcare: credit, 202104– convertible loan financing totalling €90m led by Petrichor HCM |
2021-04-22 |
| ITM–SEVERAL: credit, 202104– convertible loan financing €90m led by Petrichor HCM with undisclosed other investors |
2021-04-22 |
| Lumeon–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| Nalu Medical–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| Rapid Micro Biosystems–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| Relievant Medsystems–Endeavour Vision: investment, 202104 investment existent by EMG II Fund |
2021-04-22 |
| Atriva Therapeutics–Germany (govt): grant, 202104– up to €11.4m research funding from BMBF to advance ATR-002 for Covid-19 |
2021-04-21 |
| OxVax–Evotec: investment, 202104 seed financing round totalling €na incl co-lead investor Evotec |
2021-04-21 |
| OxVax–SEVERAL: investment, 202104 seed financing round €na from Lead Compass Investment + Evotec |
2021-04-21 |
| Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I |
2021-04-20 |
| Rinri Therapeutics–Boehringer: investment, 202104 financing round totalling £10m incl existing investor BIVF |
2021-04-20 |
| Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund |
2021-04-20 |
| Sense Biodetection–Earlybird: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Earlybird Health |
2021-04-20 |
| Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies |
2021-04-20 |
| Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m |
2021-04-20 |
| BioVersys–EU (govt): credit, 202104– venture debt loan up to €20m in three tranches from EIB |
2021-04-14 |
| Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group |
2021-04-13 |
| Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al |
2021-04-13 |
| Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers |
2021-04-13 |
| ImmunOs Therapeutics–EU (govt): grant, 202104– Eurostars-2 grant for developm of OCi antibody tog with ProteoGenix SAS + Amsterdam UMC |
2021-04-12 |
| Mestex–Grünenthal: investment, 202104 acquisition 100% of Mestex AG by Grünenthal |
2021-04-12 |
| VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market |
2021-04-08 |
| Delta 4–OTHER: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office |
2021-04-07 |
| Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office |
2021-04-07 |
| Metagenomi–SEVERAL: investment, 202104 financing round Series A extension $10m with RA Capital Management closing total Series A at $75m |
2021-04-07 |
| Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA |
2021-04-01 |
| Celeris Therapeutics–Longevitytech.fund: investment, 202103 pre-seed financing round totalling €400k incl investor Longevitytech.fund |
2021-03-31 |
| Celeris Therapeutics–R42 Group: investment, 202103 pre-seed financing round totalling €400k incl investor R42 Group |
2021-03-31 |
| Celeris Therapeutics–SEVERAL: investment, 202103 pre-seed financing round €400k from R42 Group + Longevitytech.fund |
2021-03-31 |
| OncoResponse–Helsinn: investment, 202103 financing round Series C totalling $40.6m incl existing + co-investor 3B Future Health Fund |
2021-03-31 |
| OncoResponse–SEVERAL: investment, 202103 financing round Series C $40.6m led by Magnetar Group |
2021-03-31 |
| Pyxis Oncology–Bayer: investment, 202103 financing round Series B totalling $152m incl existing + co-investor Leaps by Bayer |
2021-03-30 |
| Pyxis Oncology–HBM: investment, 202103 financing round Series B totalling $152m incl new + co-investor HBM Healthcare Investments |
2021-03-30 |
| Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience |
2021-03-30 |
| Allcyte–42cap: investment, 202103 seed financing round totalling $6m incl new investor 42cap |
2021-03-25 |
| Allcyte–Air Street Capital: investment, 202103 seed financing round totalling $6m incl new investor Air Street Capital |
2021-03-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 13 14 15 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
